Faeth 10-Q: $174.8M Cash Funds PIKTOR Trials Through Topline Data
FTH has more than doubled off its 52-week low of $7.45.
Summary
Faeth's Q3 10-Q shows a $20.4 million quarterly loss and $174.8 million in cash and securities, which management says funds both PIKTOR trials through topline data. The nine-month $206.6 million loss is dominated by a $133.0 million non-cash IPR&D charge from the February Faeth acquisition.
Key Events · Earnings and Guidance · FTH
-
Q3 Loss Widens on Trial Ramp
Net loss was $20.4 million, or $0.79 per share, versus $4.6 million a year earlier. R&D rose to $11.7 million from $2.5 million and G&A to $10.4 million from $2.3 million as PIKTOR spending scaled up.
-
Cash Covers Both PIKTOR Readouts
Cash, cash equivalents and marketable securities totaled $174.8 million at September 30, 2026, which management says funds operations through topline data from the Phase 2 endometrial trial (FTH-PIK-201) and the Phase 1b/2 breast cancer trial (FTH-PIK-101).
-
Nine-Month Loss Is Mostly Non-Cash
The $206.6 million nine-month net loss includes $133.0 million of acquired in-process R&D expensed on the February 2026 Legacy Faeth acquisition. Net cash used in operating activities was $39.4 million.
-
ATM Overhang, Nothing Sold Yet
A June 2026 sales agreement with TD Securities allows sales of up to $150.0 million of common stock from time to time; no shares have been sold under the program as of the filing date.
Analysis · FTH · Life Sciences
The headline Q3 loss of $20.4 million was already out this morning, but the 10-Q is what tells you the company is funded. Cash, equivalents and marketable securities totaled $174.8 million at September 30, and management states that covers operations through topline readouts from both the Phase 2 endometrial cancer trial and the Phase 1b/2 breast cancer trial. That removes any near-term financing need, which is the main thing that kills small biotechs between data points. The nine-month loss of $206.6 million looks alarming but is mostly accounting: $133.0 million of acquired in-process R&D was expensed on the February acquisition of Legacy Faeth, a non-cash charge. Operating cash burn for the nine months was $39.4 million. The offset is that spending is ramping fast — Q3 R&D of $11.7 million versus $2.5 million a year ago — so the runway depends on trial costs staying in the current range. A $150.0 million at-the-market program with TD Securities exists but no shares have been sold under it.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FTH was trading at $19.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $496.9M. The 52-week trading range was $7.45 to $42.14. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.